2018-01-26 9:53 - Medios AG exceeds forecast for fiscal year 2017 – Management Board optimistic for fiscal year 2018

Berlin, 26 January 2018 - Medios AG has exceeded its forecast for the fiscal year 2017 due to stronger-than-expected growth. According to preliminary calculations (IFRS), the company's consolidated sales revenue increased from January till December 2017 by 58 percent to EUR 253.0 million compared to the prior-year period (prior year EUR 160.4 million, pro-forma* IFRS). Earnings before taxes (EBT**) and special effects rose by 38 percent to EUR 8.0 million (prior year EUR 5.8 million, pro-forma* IFRS). The Management Board had expected a consolidated sales revenue amounting to EUR 230 million and an EBT before special effects amounting to EUR 7.0 million up to EUR 7.5 million.

The increase in consolidated sales revenue resulted essentially from gaining market share through the further expansion of the partner network as well as the extension of the product range in the Specialty Pharma field. The EBT takes into account negative impacts from growth investments and the prohibition of public tendering on cytostatic drugs as well as the effects of the new drug price regulation on oncological preparations. In contrast, the non-cash special effect through the stock option program, which was implemented on the basis of the resolution of the Annual General Meeting 2017 in order to incentivise the management team, is not taken into account. According to preliminary calculations, the special effect will cause an extraordinary expense amounting to around EUR 1.1 million in the fiscal year 2017.

For the fiscal year 2018, the Management Board is optimistic. A detailed forecast will be provided by Medios AG not later than April 2018 with the publication of the full consolidated financial statements 2017.

Matthias Gärtner, CFO Medios AG

* According to the securities prospectus dated 16 November 2016

** EBT is defined as net earnings before income taxes

Contact

Medios AG, Friedrichstraße 113a, 10117 Berlin

Phone: [phone]; Fax: [phone]

E-Mail: [e-mail]; www.medios.ag

About Medios AG

Medios AG is one of the leading Specialty Pharma companies in Germany. As wholesaler for Specialty Pharma drugs and GMP-certified manufacturer of patient-specific medications, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Specialty Pharma drugs are, in particular, individualised infusions for patients with rare or chronic diseases like cancer, HIV and hepatitis. It is Medios' aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Medios AG is Germany's first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.

Disclaimer

This release is a mandatory announcement pursuant to Art. 17 of the Market Abuse Regulation (MAR). The assessments contained therein are, as always, subject to the disclaimer provided below.

Cautionary note regarding forward-looking statements/No duty to update

This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.

Other

This publication constitutes neither an offer to sell nor an invitation to buy securities. It may not be published, distributed or transmitted, directly or indirectly, in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other jurisdiction where such an announcement could be unlawful. This announcement does not constitute a recommendation concerning the purchase or sale of securities described in this announcement.